Spectrum Announces Launch Of New Patient-to-Patient Educational Campaign For ZEVALIN® On ZEVALIN.com

Spectrum Pharmaceuticals (NasdaqGS: SPPI), a biotechnology company with a primary focus in oncology and hematology, announced today the launch of the Company's new patient campaign for ZEVALIN (ibritumomab tiuxetan) Injection for Intravenous Use, on ZEVALIN.com.

ZEVALIN.com debuts four multimedia patient stories from actual patients living with follicular lymphoma and treated with ZEVALIN. Jan W., Laura T., Michael W., and Dave S. all share their perspectives on life before cancer, diagnoses, treatment options, receiving ZEVALIN, and life today. ZEVALIN.com has been completely redesigned to also become an educational resource for patients, caregivers, and healthcare professionals seeking information on follicular lymphoma and ZEVALIN. While the overall re-launch campaign will continue to focus on physicians with "RRZ" (rituximab, rituximab, ZEVALIN), additional emphasis will be placed on direct-to-patient outreach and patient-to-patient education.

“The stories of these patients on ZEVALIN.com are very moving and reinforce the centrality of patients in the mission of our company,” said Rajesh C. Shrotriya, MD, Chairman, Chief Executive Officer and President of Spectrum Pharmaceuticals, Inc. “Patients today are more empowered through education to take an active role in learning about their treatment options. These four patients and their doctors chose ZEVALIN. We hope their journeys will inspire and encourage other follicular lymphoma patients to take an active role in educating themselves. Follicular lymphoma patients deserve to understand all of their options, including how one therapeutic dose of ZEVALIN could fit into their treatment plans.”

This initiative is part of a larger patient-to-patient campaign supported by print, digital, online, and personalized patient educational programs. More than ever patients are going online to learn about their disease and treatment options. ZEVALIN.com has been redesigned in part to provide a forum for patients and caregivers to learn more from other patients living with follicular lymphoma and treated with ZEVALIN.

About ZEVALIN ® and the ZEVALIN Therapeutic Regimen

ZEVALIN (ibritumomab tiuxetan) Injection for intravenous use, is indicated for the treatment of patients with relapsed or refractory, low-grade or follicular B-cell non-Hodgkin’s lymphoma (NHL). ZEVALIN is also indicated for the treatment of patients with previously untreated follicular non-Hodgkin Lymphoma who achieve a partial or complete response to first-line chemotherapy.

ZEVALIN is a CD20-directed radiotherapeutic antibody. The ZEVALIN therapeutic regimen consists of two components: rituximab, and Yttrium-90 (Y-90) radiolabeled ZEVALIN for therapy. ZEVALIN builds on the combined effect of a targeted biologic monoclonal antibody augmented with the therapeutic effects of a beta-emitting radioisotope.

Important ZEVALIN ® Safety Information

Deaths have occurred within 24 hours of rituximab infusion, an essential component of the ZEVALIN therapeutic regimen. These fatalities were associated with hypoxia, pulmonary infiltrates, acute respiratory distress syndrome, myocardial infarction, ventricular fibrillation, or cardiogenic shock. Most (80%) fatalities occurred with the first rituximab infusion. ZEVALIN administration can result in severe and prolonged cytopenias in most patients. Severe cutaneous and mucocutaneous reactions, some fatal, can occur with the ZEVALIN therapeutic regimen.

Please see full Prescribing Information, including BOXED WARNINGS, for ZEVALIN and rituximab. Full prescribing information for ZEVALIN can be found at www.ZEVALIN.com.

About Spectrum Pharmaceuticals, Inc.

Spectrum Pharmaceuticals, a biotechnology company with a primary focus in oncology and hematology, currently markets two oncology drugs, FUSILEV ® (levoleucovorin) for Injection and ZEVALIN ®(ibritumomab tiuxetan) Injection for intravenous use. In addition, Spectrum has two drugs, apaziquone and belinostat, in late stage development with a goal of filing New Drug Applications (NDAs) with the U.S. Food & Drug Administration in 2012. The Company also has a diversified pipeline of novel drug candidates. The Company’s strategy is comprised of acquiring, developing and commercializing a broad and diverse pipeline of late-stage clinical and commercial drug products. The Company has aggressive business development and commercial operation teams that support a robust drug development program encompassing clinical development, medical research, regulatory affairs, biostatistics and data management. The Company also leverages the expertise of its worldwide partners to assist in the execution of its strategy. For more information, please visit the Company’s website at www.sppirx.com.

Forward-looking statement – This press release may contain forward-looking statements regarding future events and the future performance of Spectrum Pharmaceuticals that involve risks and uncertainties that could cause actual results to differ materially. These statements are based on management’s current beliefs and expectations. These statements include but are not limited to statements that relate to our business and its future, including certain company milestones, Spectrum's ability to identify, acquire, develop and commercialize a broad and diverse pipeline of late-stage clinical and commercial products, leveraging the expertise of partners and employees, around the world to assist us in the execution of our strategy, and any statements that relate to the intent, belief, plans or expectations of Spectrum or its management, or that are not a statement of historical fact. Risks that could cause actual results to differ include the possibility that our existing and new drug candidates, may not prove safe or effective, the possibility that our existing and new applications to the FDA may not receive approval, and other regulatory agencies in a timely manner or at all, the possibility that our existing and new drug candidates, if approved, may not be more effective, safer or more cost efficient than competing drugs, the possibility that our efforts to acquire or in-license and develop additional drug candidates may fail, our lack of sustained revenue history, our limited marketing experience, our dependence on third parties for clinical trials, manufacturing, distribution and quality control and other risks that are described in further detail in the Company's reports filed with the Securities and Exchange Commission. We do not plan to update any such forward-looking statements and expressly disclaim any duty to update the information contained in this press release except as required by law.

SPECTRUM PHARMACEUTICALS, INC. ® , ZEVALIN ® , and FUSILEV ® are registered trademarks of Spectrum Pharmaceuticals, Inc. REDEFINING CANCER CARE™ and the Spectrum Pharmaceutical logos are trademarks owned by Spectrum Pharmaceuticals, Inc.

© 2012 Spectrum Pharmaceuticals, Inc. All Rights Reserved.

Copyright Business Wire 2010

If you liked this article you might like

Pacific Biosciences Shares Down After Third-Quarter Results -- Biotech Movers

Pacific Biosciences Shares Down After Third-Quarter Results -- Biotech Movers

Spectrum Shares Surge on Data for Lung Cancer Drug -- Biotech Movers

Spectrum Shares Surge on Data for Lung Cancer Drug -- Biotech Movers

Biotech Movers: Myriad Genetics, Spectrum Pharmaceuticals, Array BioPharma

Biotech Movers: Myriad Genetics, Spectrum Pharmaceuticals, Array BioPharma

Merger Buzz Drives Akorn to Top of Health Chart in April

Merger Buzz Drives Akorn to Top of Health Chart in April

Shortened FDA Advisory Panel Is Bad Omen for Puma Bio's Controversial Breast Cancer Drug

Shortened FDA Advisory Panel Is Bad Omen for Puma Bio's Controversial Breast Cancer Drug